SEC Form SC 13G/A filed by Repare Therapeutics Inc. (Amendment)

$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $RPTX alert in real time by email
SC 13G/A 1 tm244117d22_sc13ga.htm SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

SCHEDULE 13G

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

 

Repare Therapeutics Inc.

(Name of Issuer)

 

Common Shares, no par value

(Title of Class of Securities)

 

760273102

(CUSIP Number)

 

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

xRule 13d-1(b)
¨Rule 13d-1(c)
¨Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 760273102 13G Page 2 of 5 Pages 

 

1. NAMES OF REPORTING PERSONS  
ARK Investment Management LLC  
 
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(a) ¨  
(b) ¨  
3. SEC USE ONLY  
   
 
4. CITIZENSHIP OR PLACE OF ORGANIZATION  
Delaware, United States  
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5. SOLE VOTING POWER  
2,821,560  
 
6. SHARED VOTING POWER  
0  
 
7. SOLE DISPOSITIVE POWER  
2,821,560  
 
8. SHARED DISPOSITIVE POWER  
0  
 
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
2,821,560  
 
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
¨  
 
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
6.70%  
 
12. TYPE OF REPORTING PERSON  
IA  
 

 

 

 

 

CUSIP No. 760273102 13G Page 3 of 5 Pages 

 

Item 1(a) Name of issuer:

 

Repare Therapeutics Inc.

 

Item 1(b) Address of issuer's principal executive offices:

 

7171 Frederick Banting, Suite 270, Building 2

Saint-Laurent, Québec, Canada H4S 1Z9

 

Item 2(a) Name of person filing:

 

ARK Investment Management LLC

 

Item 2(b) Address or principal business office or, if none, residence:

 

ARK Investment Management LLC

200 Central Avenue

St. Petersburg, FL 33701

 

Item 2(c) Citizenship:

 

Delaware, United States

 

Item 2(d) Title of class of securities:

 

Common Shares, no par value

 

Item 2(e) CUSIP No.:

 

760273102

 

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

 

(b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

 

(c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

 

(d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

 

(e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

 

(f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

(g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 

(h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

(j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

 

(k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

 

 

 

 

CUSIP No. 760273102 13G Page 4 of 5 Pages 

 

Item 4. Ownership

 

(a)Amount beneficially owned:

 

2,821,560

 

(b)Percent of class:

 

6.70%

 

(c)Number of shares as to which such person has:

 

(i)Sole power to vote or to direct the vote:  2,821,560

 

(ii)Shared power to vote or to direct the vote:  0

 

(iii)Sole power to dispose or to direct the disposition of:  2,821,560

 

(iv)Shared power to dispose or to direct the disposition of:  0

 

Item 5. Ownership of 5 Percent or Less of a Class.

 

Not applicable.

 

Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

 

To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the shares which represents more than five percent of the number of outstanding class of the shares.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

 

 

 

CUSIP No. 760273102 13G Page 5 of 5 Pages 

 

Item 10. Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

The reporting persons agree that this statement is filed on behalf of each of them.

 

Dated:    January 29, 2024

 

  ARK Investment Management LLC  
     
  By: /s/ Kellen Carter
    Name:  Kellen Carter
    Title:    Chief Compliance Officer

 

 

 

Get the next $RPTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RPTX

DatePrice TargetRatingAnalyst
6/9/2023$11.00 → $16.00Hold → Buy
Stifel
2/3/2023$28.00 → $15.00Overweight → Equal-Weight
Morgan Stanley
1/6/2023$28.00Overweight
CapitalOne
4/12/2022$11.00Buy → Hold
Stifel
3/17/2022$43.00Buy
Goldman
9/23/2021$48.00Buy
Stifel
9/13/2021$54.00Buy
HC Wainwright & Co.
8/16/2021$45.00 → $47.00Overweight
Morgan Stanley
More analyst ratings

$RPTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced that the Compensation Committee of the Company's Board of Directors granted, on November 5, 2024 and March 5, 2025, stock options to purchase an aggregate of 22,200 of the Company's common shares to two individuals pursuant to the Company's 2024 Inducement Plan. The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Repare, as an inducement material to such individual's entering into employment with Repare, in accordance with Nasdaq Listing Rule 5635(c)(4). Repare

    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

    Initial clinical readout from Phase 1 RP-3467 (Polθ ATPase/helicase inhibitor) POLAR trial expected in Q3 2025 Initial clinical readout from Phase 1 RP-1664 (PLK4 inhibitor) LIONS trial expected in Q4 2025 Company reducing its workforce by approximately 75% $152.8 million in cash and cash equivalents and marketable securities provides runway to late-2027 Exploring partnerships across portfolio, including for Lunre+Camo Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2024. "Our recently implemented re-structuring and the re-prio

    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

    Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025 Exploring partnerships for continued development of Lunre+Camo and other assets Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced a re-alignment of resources and a re-prioritization of its clinical portfolio to focus on the continued advancement of its Phase 1 clinical programs, RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor). Repare also announced its intention to seek partnering opp

    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RPTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RPTX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$RPTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RPTX
SEC Filings

See more

$RPTX
Leadership Updates

Live Leadership Updates

See more
  • Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

    Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D             First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effecti

    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board. "On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare

    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

    Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. "We significantly advanced our pipeline in 2023 and presented strong data from key programs, notably for lunresertib in combination with camonsertib, and for camonsertib in combination with PARP inhibitors. In addition, we presented compelling preclinical data sets for RP-3467, which we're developing as a potential best-in-class Polθ inhibitor, and for RP-1664, a potential first- and best-in-class PLK4 inhibitor," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "2

    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RPTX
Financials

Live finance-specific insights

See more
  • Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

    Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte

    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

    Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,

    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • The Week in Canadian Press Releases: 10 Stories You Need to See

    A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, May 31, 2024 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that

    $CM
    $RPTX
    $RY
    Commercial Banks
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RPTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more